Xiamen AmonMed Biotechnology Co., Ltd., was established in 2014 , incubated by the Chinese Academy of Sciences, invested by LETS GROUP (a listed company with stock code 002398 in A-shares). We focus on the deep research for the global strategy of scarce resources "rare earth", and highly value on the research and production for in vitro diagnostic products and equipment. Our products have been sold to more than 20 countries around the world and many cities in China.

AmonMed is a rare earth biomedical enterprise incubated by the Chinese Academy of Sciences, we have a strong technical team led by Academician Hong Maochun, and relying on the scientific research platform of the Chinese Academy of Sciences. AmonMed has undertaken and completed a number of projects for national and Chinese Academy of Sciences. So far, there are twelve patents of rare earth biological medicine, and successfully developed a series of exclusive the rare earth nano fluorescence immunity in vitro diagnostic products with independent intellectual property rights, including thirty-four products with the CE certification, thirty-eight in vitro diagnostic reagents, and two rare earth nano fluorescence immunoassay analyzer with certificate of National Medical Products Administration. Products include COVID-19 test kit, myocardial triple test kit, C-reactive protein test kit, D-dimer test kit and so on.